& beckwith-wiedemann syndrome

9
& Beckwith-Wiedemann Syndrome Brandon Ballance p57 April 2 nd 2013

Upload: yon

Post on 24-Feb-2016

110 views

Category:

Documents


0 download

DESCRIPTION

p57. April 2 nd 2013. & Beckwith-Wiedemann Syndrome. Brandon Ballance. Beckwith-Wiedemann Syndrome. Risk of developing cancer : 7.5%. Genes Associated with BWS. CDKN1C. Genetic Imprinting. 1 in 13,700 Children . Only MATERNAL allele expressed!. CH 3. CH 3. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: & Beckwith-Wiedemann                 Syndrome

&

Beckwith-Wiedemann

Syndrome

Brandon Ballance

p57

April 2nd 2013

Page 2: & Beckwith-Wiedemann                 Syndrome

Beckwith-Wiedemann Syndrome

Risk of developing cancer: 7.5%

Page 3: & Beckwith-Wiedemann                 Syndrome

Genes Associated with BWS

CDKN1C

Page 4: & Beckwith-Wiedemann                 Syndrome

Genetic Imprinting 1 in 13,700

Children

CH3

CH3

Only MATERNAL allele expressed!

Page 5: & Beckwith-Wiedemann                 Syndrome

Familial Inheritance Pattern

Mutated maternal allele = BWS

Mutated paternal allele =

CARRIERUPD

Page 6: & Beckwith-Wiedemann                 Syndrome

What Does the Protein Do?

G1 Cyclin-CDK

Complexes

p57 (KIP2)

= TUMOR SUPPRESSORp57

CDKN1C

Page 7: & Beckwith-Wiedemann                 Syndrome

Model Organism: Knockout Mice

NO tumors developed

Page 8: & Beckwith-Wiedemann                 Syndrome

Grafted Prostates from Null Mice

Tumors!

Page 9: & Beckwith-Wiedemann                 Syndrome

Works Cited: "Beckwith-Wiedemann Syndrome." Humpath.com. N.p., 17 Sept. 2003. Web. <http://www.humpath.com/spip.php?article824>.Hatada, I., Mukai, T. Genomic imprinting of p57(KIP2), a cyclin-dependent kinase inhibitor, in mouse. Nature Genet. 11: 204- 206, 1995. Jin RJ, et al. Down-regulation of p57(Kip2) induces prostate cancer in the mouse. Cancer Res. 2008;68:3601-3608. Lee, M.-H., Reynisdottir, I., Massague, J. Cloning of p57(KIP2), a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9: 639-649, 1995.Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. p57KIP2: “Kip”ing the cell under control. Mol. Cancer Res. 2009;7:1902-1919.Pilu, Gianluigi. "The Global Library of Women’s Medicine." Ultrasound Atlas. The International Society of Ultrasound in Obstetrics & Gynecology, n.d. Web. <http://www.glowm.com/ultrasoundAtlas>.Sparago A., Russo S., Cerrato F., Ferraiuolo S., Castorina P., Selicorni A., Schwienbacher C., Negrini M., Ferrero G.B., Silengo M.C., et al. Mechanisms causing imprinting defects in familial Beckwith–Wiedemann syndrome with Wilms’ tumour. Hum. Mol. Genet. 2007;16:254-264.Tunster SJ, Van De Pette M, John RM. Fetal overgrowth in the Cdkn1c mouse model of Beckwith-Wiedemann syndrome. DMM Disease Models and Mechanisms. 2011;4(6):814–821."What Is Beckwith Wiedemann Syndrom?" Assisting Families and Individuals Affected with BWS. Beckwith Wiedemann Children's Assn of NZ (Inc), n.d. Web. <http://www.bwcanz.org/What-is-Beckwith-Wiedemann-Syndrome-.php>.